Selinexor and Docetaxel in Treating Patients With Recurrent or Metastatic Squamous Cell Lung Cancer
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Clinical Trials Related to Selinexor
Related studies linked through entity extraction aliases.
Phase I/II, Study of Selective Inhibitor of Nuclear Export (SINE) Selinexor (KPT-330) + Sorafenib in Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
Selinexor in Treating Patients With Intermediate- and High-Risk Acute Myeloid Leukemia or High-Risk Myelodysplastic Syndrome After Transplant
- Status
- COMPLETED
- Phase
- PHASE1
Novel Combination Therapy in the Treatment of Relapsed and Refractory Aggressive B-Cell Lymphoma
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE2
Efficacy & Safety Study of KPT-330 in Erythropoietin-Refractory Lower-Risk Myelodysplastic Syndrome Patients
- Status
- WITHDRAWN
- Phase
- PHASE2
Phase IB Study to Evaluate the Safety of Selinexor (KPT-330) in Combination With Multiple Standard Chemotherapy or Immunotherapy Agents in Patients With Advanced Malignancies
- Status
- TERMINATED
- Phase
- PHASE1
Study of CLAG + Selinexor in Relapsed or Refractory Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1/PHASE2
A Study of Selinexor in Combination With Daunorubicin and Cytarabine for Untreated AML
- Status
- COMPLETED
- Phase
- PHASE1
Phase 2 Trial of Selinexor (KPT-330) for Metastatic Triple Negative Breast Cancer (TNBC)
- Status
- COMPLETED
- Phase
- PHASE2
Study of Selinexor (KPT- 330), Lenalidomide, & Dexamethasone in Relapsed/Refractory Multiple Myeloma Patients
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Phase 1 Trial To Evaluate mFOLFOX6 With Selinexor In Patients With Metastatic Colorectal Cancer
- Status
- TERMINATED
- Phase
- PHASE1
Study of Safety, Tolerability, and Pharmacokinetics of Topical Selinexor (KPT-330) Diabetic Foot Ulcer (DFU) Patients
- Status
- WITHDRAWN
- Phase
- PHASE1/PHASE2
Selinexor in Treating Patients With Relapsed Small Cell Lung Cancer
- Status
- TERMINATED
- Phase
- PHASE2
Selinexor and Backbone Treatments of Multiple Myeloma Patients
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- PHASE1/PHASE2
Selinexor Treatment of Refractory Myeloma
- Status
- COMPLETED
- Phase
- PHASE2
Selinexor in Treating Younger Patients With Recurrent or Refractory Solid Tumors or High-Grade Gliomas
- Status
- COMPLETED
- Phase
- PHASE1
Efficacy and Safety Study of Selinexor in Relapsed or Refractory Peripheral T-cell Lymphoma or Cutaneous T-cell Lymphoma
- Status
- TERMINATED
- Phase
- PHASE2
Selinexor and Ibrutinib in Treating Patients With Relapsed or Refractory Chronic Lymphocytic Leukemia or Aggressive Non-Hodgkin Lymphoma
- Status
- COMPLETED
- Phase
- PHASE1
Selinexor and Chemotherapy in Treating Patients With Relapsed or Refractory Acute Myeloid Leukemia
- Status
- COMPLETED
- Phase
- PHASE1
Selinexor in Combination With Irinotecan in Adenocarcinoma of Stomach and Distal Esophagus
- Status
- TERMINATED
- Phase
- PHASE1